Characteristics of CD4+ CD25+ FoxP3+ Treg cells in patients with myelodysplastic syndrome and the effect of cyclosporine

中国综合临床 Pub Date : 2020-03-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2020.02.014

Zeng-sheng Wang, Yan Li, Tao Lang, Xiao-yan Zhang, L. Fu, H. Ai, Xiaoming Wang

{"title":"Characteristics of CD4+ CD25+ FoxP3+ Treg cells in patients with myelodysplastic syndrome and the effect of cyclosporine","authors":"Zeng-sheng Wang, Yan Li, Tao Lang, Xiao-yan Zhang, L. Fu, H. Ai, Xiaoming Wang","doi":"10.3760/CMA.J.ISSN.1008-6315.2020.02.014","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the expression levels of CD4+ CD25+ FOXP3+ Treg cells and interleukin(IL)-10 in serum of patients with myelodysplastic syndrome (MDS) - refractory anemia (RA) and refractory hematopenia with multilineage dysplasia (RCMD), and to evaluate the effect of cyclosporine on CD4+ CD25+ FOXP3+ Treg cells in MDS patients. \n \n \nMethods \nFrom January 2016 to January 2018, 25 MDS-RA and RCMD patients and 13 healthy controls were selected from people′s Hospital of Xinjiang Uygur Autonomous Region for retrospective analysis.The expression of CD4 + CD25 + Foxp3 + Treg and IL-10 in peripheral blood samples were detected by flow cytometry and enzyme-linked immunosorbent assay.The expression of CD4 + CD25 + Foxp3 + Treg and IL-10 in MDS-RA and RCMD patients before and 6 months after the treatment with CSA based immunosuppressive regimen was detected. \n \n \nResults \nOf the 25 patients, 13 (52%) were effective and 12 (48%) were ineffective.The proportion of CD4 + CD25 + Foxp3 + Treg in CD4 + T cells of MDS group was significantly higher than that of healthy control group [(0.37 ± 0.10)% and (0.12 ± 0.06)% respectively, t= 2.02, P< 0.001]. The level of IL 10 in MDS group was significantly higher than that in healthy control group ((7.16±1.27) μg /L and (2.75 ± 1.06) μg /L, t= 2.03, P< 0.001). The ratio of CD4 + CD25 + Foxp3 + Treg cells in MDS group was lower than that in MDS Group ((0.15±0.06)% and (0.26±0.08%), t= 1.71, P< 0.001), and the level of IL 10 in MDS group was lower than that in MDS Group ((3.22±1.01) μg /L and (4.25±1.22) μg /L, t= 2.06, P= 0.030). The proportion of CD4 + CD25 + Foxp3 + Treg in peripheral blood of 25 MDS patients was positively correlated with the level of IL-10 expression (r= 0.35, P= 0.02). \n \n \nConclusion \nThe expression of CD4+ CD25+ FOXP3+ Treg cells and IL-10 increased in MDS patients increased, but decreased after cyclosporine treatment. \n \n \nKey words: \nMyelodysplastic syndrome; CD4+ CD25+ FOXP3+ Treg cells; Interleukin 10","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2020.02.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the expression levels of CD4+ CD25+ FOXP3+ Treg cells and interleukin(IL)-10 in serum of patients with myelodysplastic syndrome (MDS) - refractory anemia (RA) and refractory hematopenia with multilineage dysplasia (RCMD), and to evaluate the effect of cyclosporine on CD4+ CD25+ FOXP3+ Treg cells in MDS patients. Methods From January 2016 to January 2018, 25 MDS-RA and RCMD patients and 13 healthy controls were selected from people′s Hospital of Xinjiang Uygur Autonomous Region for retrospective analysis.The expression of CD4 + CD25 + Foxp3 + Treg and IL-10 in peripheral blood samples were detected by flow cytometry and enzyme-linked immunosorbent assay.The expression of CD4 + CD25 + Foxp3 + Treg and IL-10 in MDS-RA and RCMD patients before and 6 months after the treatment with CSA based immunosuppressive regimen was detected. Results Of the 25 patients, 13 (52%) were effective and 12 (48%) were ineffective.The proportion of CD4 + CD25 + Foxp3 + Treg in CD4 + T cells of MDS group was significantly higher than that of healthy control group [(0.37 ± 0.10)% and (0.12 ± 0.06)% respectively, t= 2.02, P< 0.001]. The level of IL 10 in MDS group was significantly higher than that in healthy control group ((7.16±1.27) μg /L and (2.75 ± 1.06) μg /L, t= 2.03, P< 0.001). The ratio of CD4 + CD25 + Foxp3 + Treg cells in MDS group was lower than that in MDS Group ((0.15±0.06)% and (0.26±0.08%), t= 1.71, P< 0.001), and the level of IL 10 in MDS group was lower than that in MDS Group ((3.22±1.01) μg /L and (4.25±1.22) μg /L, t= 2.06, P= 0.030). The proportion of CD4 + CD25 + Foxp3 + Treg in peripheral blood of 25 MDS patients was positively correlated with the level of IL-10 expression (r= 0.35, P= 0.02). Conclusion The expression of CD4+ CD25+ FOXP3+ Treg cells and IL-10 increased in MDS patients increased, but decreased after cyclosporine treatment. Key words: Myelodysplastic syndrome; CD4+ CD25+ FOXP3+ Treg cells; Interleukin 10

查看原文本刊更多论文

骨髓增生异常综合征患者CD4+ CD25+ FoxP3+ Treg细胞的特征及环孢素的影响

目的研究骨髓增生异常综合征（MDS）-难治性贫血（RA）和难治性血细胞减少伴多谱系发育不良（RCMD）患者血清中CD4+CD25+FOXP3+Treg细胞和白细胞介素（IL）-10的表达水平，评价环孢菌素对MDS患者CD4+CD25+FOXP3+Treg细胞的影响。方法选择2016年1月至2018年1月新疆维吾尔自治区人民医院收治的25例MDS-RA和RCMD患者和13名健康对照进行回顾性分析。流式细胞仪和酶联免疫吸附法检测外周血CD4+CD25+Foxp3+Treg和IL-10的表达。检测基于CSA的免疫抑制方案治疗前和治疗后6个月MDS-RA和RCMD患者CD4+CD25+Foxp3+Treg和IL-10的表达。结果25例患者中，有效13例（52%），无效12例（48%）。MDS组CD4+T细胞中CD4+CD25+Foxp3+Treg的比例显著高于健康对照组[分别为（0.37±0.10）%和（0.12±0.06）%，T=2.02，P<0.001]，CD4+CD25+Foxp3+Treg细胞比例MDS组低于MDS组（（0.15±0.06）%和（0.26±0.08%），t=1.71，P<0.001），IL-10水平MDS组低于（3.22±1.01）μg/L和（4.25±1.22）μg/L，t=2.06，CD4+CD25+Foxp3+Treg在25例MDS患者外周血中的比例与IL-10的表达呈正相关（r=0.35，P=0.02）。关键词：骨髓增生异常综合征；CD4+CD25+FOXP3+Treg细胞；白细胞介素10

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.